Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

A case for developing North-South partnerships for research in sickle cell disease.

Weatherall D, Hofman K, Rodgers G, Ruffin J, Hrynkow S.

Blood. 2005 Feb 1;105(3):921-3. Epub 2004 Oct 5.

2.

Chemical and functional analysis of hydroxyurea oral solutions.

Heeney MM, Whorton MR, Howard TA, Johnson CA, Ware RE.

J Pediatr Hematol Oncol. 2004 Mar;26(3):179-84.

PMID:
15125610
3.

Malignancy in patients with sickle cell disease.

Schultz WH, Ware RE.

Am J Hematol. 2003 Dec;74(4):249-53.

4.

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Blood. 2004 Mar 15;103(6):2039-45. Epub 2003 Nov 20.

5.

Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.

Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliott J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA, Cannon MJ, Eckman JR, Keyserling H, Sullivan K, Wong WY, Wang WC.

J Pediatr. 2003 Oct;143(4):438-44. Erratum in: J Pediatr. 2004 Mar;144(3):412.

PMID:
14571216
6.

Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC disease.

Huang Y, Ananthakrishnan T, Eid JE.

Am J Hematol. 2003 Oct;74(2):125-6.

7.

Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children.

Rice HE, Oldham KT, Hillery CA, Skinner MA, O'Hara SM, Ware RE.

Ann Surg. 2003 Feb;237(2):281-8.

8.

Streptococcus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease.

Hord J, Byrd R, Stowe L, Windsor B, Smith-Whitley K.

J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):470-2.

PMID:
12218595
9.

Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease.

Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, Vichinsky EP, DeBaun MR, Guarini L, Zimmerman RA, Younkin DP, Gallagher DM, Kinney TR.

Blood. 2002 Apr 15;99(8):3014-8.

10.

Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease.

Santos A, Pinheiro V, Anjos C, Brandalise S, Fahel F, Lima M, Etchebehere E, Ramos C, Camargo EE.

Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):536-41. Epub 2002 Feb 15.

PMID:
11914893
11.

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

J Pediatr. 2002 Feb;140(2):225-9.

PMID:
11865275
12.

Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.

Gladwin MT, Shelhamer JH, Ognibene FP, Pease-Fye ME, Nichols JS, Link B, Patel DB, Jankowski MA, Pannell LK, Schechter AN, Rodgers GP.

Br J Haematol. 2002 Feb;116(2):436-44.

PMID:
11841449
13.

A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.

Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE.

J Pediatr. 2001 Dec;139(6):790-6.

PMID:
11743503
14.

Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, Devalck C, Dresse MF, Feremans W, Hunninck K, Toppet M, Philippet P, Van Geet C, Sariban E.

Blood. 2001 Jun 1;97(11):3628-32.

15.

Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.

Hoppe C, Vichinsky E, Quirolo K, van Warmerdam J, Allen K, Styles L.

J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):330-4.

PMID:
10959903
16.

Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin.

Hillery CA, Du MC, Wang WC, Scott JP.

Br J Haematol. 2000 May;109(2):322-7.

PMID:
10848818
17.

Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease.

Wigfall DR, Ware RE, Burchinal MR, Kinney TR, Foreman JW.

J Pediatr. 2000 Jun;136(6):749-53.

PMID:
10839871
18.

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.

Blood. 1999 Sep 1;94(5):1550-4.

19.

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.

PMID:
10326220
20.

Partial splenectomy in children under 4 years of age with hemoglobinopathy.

Idowu O, Hayes-Jordan A.

J Pediatr Surg. 1998 Aug;33(8):1251-3.

PMID:
9721997

Supplemental Content

Support Center